Research
Hormonal
Compared to PAP+semaglutide, PAP+tirzepatide showed lower incident PH at 1 year (RR:0.51) and 3 years (RR:0.42) and lower all-cause mortality at 1 year (RR:0.41) and 3 years (RR:0.33).
Tirzepatide may offer enhanced benefits over semaglutide for reducing PH and mortality in obese patients with OSA on PAP.
StrongSupportsmedium confidence
Compared to PAP+semaglutide, PAP+tirzepatide showed lower incident PH at 1 year (RR:0.51; 95% CI:0.40–0.65, NNT=77) and 3 years (RR:0.42; 95% CI:0.34–0.51, NNT=39) and lower all-cause mortality at 1 year (RR:0.41; 95% CI:0.34–0.49, NNT=40) and 3 years (RR:0.33; 95% CI:0.28–0.39, NNT=22);
Why this rating
Based on the large cohort size and retrospective study design.
Source
Adjunctive GLP-1 Receptor Agonist Therapy Lowers Incident Pulmonary Hypertension and All-cause Mortality in Obese Patients with Obstructive Sleep Apnea Treated with PAP
Samuel Governor et al. · medRxiv · 2026
cohort · n=288587Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →